Cenobamate

西诺氨酯

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameCenobamate
Drug Alias Name塞诺氨酯Cenobamatum西诺氨酯Cenobamato森巴考特 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channel alpha subunit blockersGamma-aminobutyric acid A receptor modulators
TargetsSodium channel alpha subunitGamma-aminobutyric acid A receptor
Therapy Area/IndicationsSeizuresEpilepsy, GeneralizedEpilepsies, Partial +[6] 
Global Approved IndicationsSeizuresEpilepsies, PartialEpilepsy
Approved Indications in ChinaEpilepsies, Partial
Original Approved Country/TerritoryUnited States
Original Approved Date2019/11/21
Country/TerritoryCzechiaBulgariaCanada +[26] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSK Biopharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesEurofarma LaboratoriosThe Brigham and Women's HospitalInsignis Therapeutics Inc +[12] 
Inactive CompaniesN/A
Active IndicationsSeizuresEpilepsy, GeneralizedEpilepsies, Partial +[5] 
Inactive IndicationsNervous System Diseases

Other Information

ATC CodeN03A
Related LinksDrugBankKEGG